IDEXX Laboratories Inc.
IDXX | NASDAQ
$507.61
-$4.04 (-0.79%)
Sep 21, 2026, 9:39 AM ET · Market open
Company Profile
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
Key Executives
| Name | Position |
|---|---|
| Michael Erickson | President, Chief Executive Officer & Director |
| Andrew Emerson | Executive Vice President, Chief Financial Officer & Treasurer |
| Amit Gupta | Senior VP, Chief Digital & Information Officer |
| Bob Asmann | Senior Vice President of Global Operations |
| Jonathan J. Mazelsky | Executive Chairman |
| Julie Godon | Senior Vice President & Global Marketing Officer |
| Martin Smith | Executive Vice President of Global Operations and R&D |
| Michael J. Lane | Executive Vice President and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology |
| Michael Johnson | Executive Vice President & Chief Human Resources Officer |
| Nimrata Khatra Hunt | Advisor |
| Sharon E. Underberg | Executive Vice President, General Counsel, & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 24, 2026 | 4 | Filing |
| Aug 04, 2026 | 10-Q | Quarterly Report |
| Aug 04, 2026 | 8-K | Current Report |
| Aug 03, 2026 | 4 | Filing |
| Jun 02, 2026 | 4 | Filing |
| Jun 01, 2026 | SD | Filing |
| May 15, 2026 | 8-K | Current Report |
| May 14, 2026 | 4 | Filing |
| May 14, 2026 | 4 | Filing |
| May 14, 2026 | 4 | Filing |
IDEXX Laboratories Inc.
| Country | United States |
| IPO Date | Jun 20, 1991 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 11,000 |
| CEO | Michael Erickson |
Contact Details
One IDEXX Drive Westbrook,
Maine 04092 United States
Stock Details
| Ticker Symbol | IDXX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000874716 |
| CUSIP Number | 45168D104 |
| ISIN Number | US45168D1046 |
| SIC Code | 2835 |
Recent News
- 8 hours ago / defenseworld.netIDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets
- 8 hours ago / defenseworld.netIDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference
- 4 days ago / zacks.comIDEXX Stock Gains Following the Acquisition of CoVet
- 4 days ago / businesswire.comIDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
- 5 days ago / businesswire.comIDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
- 7 days ago / seekingalpha.comIDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 11 days ago / fool.comInsider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock
- 18 days ago / zacks.comIdexx (IDXX) Down 7.8% Since Last Earnings Report: Can It Rebound?
- 21 days ago / gurufocus.comIDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
- 21 days ago / zacks.comIdexx Laboratories (IDXX) is a Top-Ranked Growth Stock: Should You Buy?
Add to Watchlist
Select watchlists to add or remove IDXX